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Objective: Activation of the Liver X Receptor (LXR) has recently been identiﬁed as a therapeutic strategy for
osteoarthritis (OA). Human OA articular cartilage explants show decreased LXR expression, and LXRb-null
mice display OA-like symptoms. LXR agonist administration to OA articular cartilage explants suppresses
proteoglycan degradation and restores LXR-activated transcription. We aimed to investigate the effect of
LXR activation on chondrocyte differentiation to elucidate themolecularmechanisms behind its protection
against OA.
Method: The speciﬁc LXR agonist, GW3965, was used to examine the effect of LXR activation on chon-
drocyte differentiation. Tibia organ cultures were used to examine the effect of LXR activation on bone
growth and growth plate morphology, followed by immunohistochemical analysis. In ATDC5 and
micromass cultures, chondrocyte differentiation was examined through cellular staining and prolifera-
tion assays. Various chondrogenic markers were analyzed by real-time reverse-transcription polymerase
chain reaction (qRT-PCR) in micromass RNA.
Results: Chondrocyte hypertrophy was suppressed by GW3965 treatment, as shown by decreased
hypertrophic zone length in the tibial growth plate, decreased alkaline phosphatase staining in ATDC5
and micromass cultures, and down regulation of Col10a1, Mmp13 and Runx2 expression. Increased
proliferation in treated ATDC5 cells and up-regulation of Col2a1 expression in treated micromass cultures
suggest hypertrophy is suppressed secondary to prolonged proliferation. Decreased p57 levels in treated
growth plates suggest this to be due to cell-cycle exit delay.
Conclusion: Our ﬁndings regarding LXR's role in cartilage development provide insight into how LXR
activation prevents cartilage breakdown, further solidifying its potential as a therapeutic target of OA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Longitudinal bone growth in the body is attributed to the ac-
tivity of the growth plate in the process of endochondral ossiﬁca-
tion, in which a cartilage template intermediate is formed and then
replaced by bone speciﬁc matrix1. Endochondral ossiﬁcation begins
with the condensation of mesenchymal cells, which then initiate
chondrogenic differentiation under the control of the transcription
factor Sox92,3. These chondrocytes ﬁrst proliferate while producing
extracellular matrix rich in collagen II and proteoglycan (aggrecan),
then exit the cell cycle and undergo hypertrophy starting from the
center of the cartilage anlage2,4,5. The hypertrophic chondrocytes
initiate mineralization of their matrix and undergo apoptotic cellto: F. Beier, Department of
n Ontario, London, Ontario,
519-661-3827.
fbeier@uwo.ca (F. Beier).
ternational. Published by Elsevier Ldeath2. This allows the invasion of blood vessels, osteoblasts, and
osteoclasts to remove the cartilage matrix for the deposition of
bone matrix, ultimately forming the primary ossiﬁcation center2,5.
Postnatally, chondrocytes at the two distal ends of the bone un-
dergo a similar differentiation process to form the secondary ossi-
ﬁcation centers6. The developing cartilage that remains between
the primary and the secondary ossiﬁcation centers is deﬁned as the
growth plate, consisting of distinct cell layers of resting, prolifera-
tive and hypertrophic zones1,2. While many markers of chon-
drocyte differentiation are known, many nuclear factors and
signalingmolecules regulating this process remain to be elucidated.
Certain characteristics of osteoarthritis (OA) have been found to
resemble the endochondral ossiﬁcation process7. As opposed to
growth plate chondrocytes that are much more dynamic, healthy
articular chondrocytes remain in a stable state and do not differ-
entiate further8. However, osteoarthritic articular chondrocytes
lose their stable state and can initiate behavior similar to growth
plate chondrocytes, such as proliferation, terminal differentiationtd. All rights reserved.
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zymes such as matrix metalloproteinase (MMP)-13 and aggreca-
nases produced by hypertrophic chondrocytes to degrade their
surrounding matrix within the growth plate are also produced in
OA cartilage13. As such, it is reasonable to postulate that signaling
molecules involved in the pathogenesis of OA may also be involved
in regulating chondrocyte differentiation of the growth plate14.
The Liver X Receptors (LXRa/NR1H3 and LXRb/NR1H2) are nu-
clear receptors best known for their central roles in regulation of
lipid metabolism and inﬂammatory signaling15e17. However, recent
studies have suggested LXR to possess roles in cartilage that offer
protection against OA. LXRb-null mice display OA-like symptoms,
including proteoglycan degradation and prostaglandin-E2 pro-
duction in the articular cartilage18. Furthermore, human OA artic-
ular cartilage explants exhibit decreased LXRa and LXRb
expression19. Interestingly, the administration of synthetic LXR
agonists to human OA articular cartilage explants suppresses pro-
teoglycan degradation and restores LXR-activated transcription18,19.
However, the cellular and molecular mechanisms underlying LXR's
protective role in cartilage are not completely understood.
In this study, we hypothesize that LXR plays a role in the regu-
lation of chondrocyte differentiation, speciﬁcally by controlling
chondrocyte hypertrophy. To test our hypothesis, the speciﬁc LXR
agonist, GW3965, was used to examine the effect of LXR activation
on different culture systems. Markers of chondrogenic differentia-
tion were subsequently analyzed at the mRNA and protein level to
help elucidate underlyingmechanisms. Our ﬁndings show that LXR
activation using a synthetic agonist results in enhanced chon-
drocyte proliferation and reduced chondrocyte hypertrophy. These
results suggest LXR's role in regulating endochondral ossiﬁcation to
be a possible mechanism in protection against OA.
Materials and methods
Timed pregnant CD1 mice were purchased from Charles River
Laboratories (St. Constant, QC). All procedures involving mice were
conducted following the animal protocol approvedby theUniversity
of Western Ontario Animal Care and Use Committee. All organ cul-
ture and cell culture media components were from SigmaeAldrich
(Oakville, ON), Gibco (Life Technologies Inc, Burlington, ON), and
Invitrogen (Life Technologies Inc, Burlington, ON) unless otherwise
stated. The LXR agonist, GW3965, was purchased from Sigma-
eAldrich. All real-time PCR reagents and probes were purchased
from Applied Biosystems (Life Technologies Inc, Burlington, ON).
Tibia organ culture
Tibiae were isolated from E15.5 CD1 mice and cultured in media
as previously described20e23. Tibiae were then incubated for 6 days.
Treatment commenced the day following tibia isolation (day 1)
using dimethylsulfoxide (DMSO) (SigmaeAldrich) as the vehicle,
and the LXR agonist GW3965 at concentrations of 1 mM, 2 mM, 5 mM
and 10 mM.Measurements of bone length were taken on day 1 prior
to treatment using both the Zeiss Stemi SV6 Stereo Zoom micro-
scope with eyepiece, as well as the Leica EC3 microscope and Leica
Application Suite V3 Software (Leica Microsystems Inc, Concord,
ON). Mediawith treatment were changed every other day, and after
6 days another measurement was taken. The calculated difference
in tibia length between time-points was used as a measure of bone
growth.
Histology
Tibiae explantswere rinsedwith phosphate buffered saline (PBS)
and ﬁxed overnight in 4% paraformaldehyde (PFA) (SigmaeAldrich).Tibiae were then marked with 2% mercurochrome, placed in 70%
ethanol, and sent for embedding and sectioning at the Robarts
Research Institute,Molecular and Pathology (London, ON). Safranin-
O/Fast Green staining was performed as described with minor
modiﬁcations22. Afterdewaxing inxylene and rehydration in a series
of graded alcohol washes, sections were incubated in hematoxylin
for 2 min, 0.02% Fast Green (Harleco, Darmstadt, Germany) for
25min followed by 7 dips in 1% acetic acid solution, and ﬁnally 0.1%
Safranin-O (SigmaeAldrich) for 7 min. Slides were then dehydrated
and mounted using a xylene-based mounting media. Histological
quantiﬁcation was performed on stained sections through the
measuring of the length of individual growth plate zones as well as
the total growth plate. On all sections, the length of the total growth
platewas ﬁrst identiﬁed, followed by the hypertrophic zone and the
proliferative and resting zones collectively. All measurements were
done using the distance line tool on Leica Application Suite V3
Software.
Immunohistochemistry (IHC)
Parafﬁn sections were dewaxed and rehydrated followed by in-
cubation in 3%H2O2. Sectionswere then boiled in sodiumcitrate (pH
6.0), blocked with 5% goat serum in PBS, and incubated with Kip2/
p57 primary antibody (sc-8298, Santa Cruz Biotechnology, Santa
Cruz, CA) at 4C overnight with secondary antibody subsequently
applied24. After colorimetric detection with diaminobenzidine
(DAB) (Dako, Markham, ON) substrate solution, sections were
counterstained with methyl green and mounted. Quantiﬁcation of
IHC was performed by counting all positively stained (brown) cells
within a 58.48  107.53 mm area of interest. All values presented
were absolute numbers of positively stained cells in control or
GW3965-treated growth plates. All images were captured using the
Leica DFC295 microscope and Leica Application Suite V3 Software.
ATDC5 cell culture
ATDC5 cells were cultured and induced to differentiate with 1%
insulinetransferrineselenium (ITS) (SigmaeAldrich) the day after
plating as described25e27. Cells were plated at a density of
2  104 cells/ml in 24-well plates for a period of 18 days. Treatment
was commenced on day 3 with DMSO as the vehicle or 1 mM
GW3965. Media including treatment were changed every other day
throughout the entire time-course.
Proliferation assays
Thiazolyl blue tetrazolium bromide (MTT) proliferation assay
was performed as described with minor modiﬁcations25,28. ATDC5
cells were plated at 2  104 cells/ml in 24-well plates. Cells were
treated with DMSO or 1 mM GW3965 for a period of 15 days, with
media changed every other day. On days 3, 6, 9, 12, and 15, 1:10
dilution of 5 mg/mLMTT (SigmaeAldrich) in PBS was added to cells
and incubated for 4 h at 37C. Solubilization using acidiﬁed iso-
propanol (0.04 M HCl in absolute isopropanol) followed, and
the converted dye was quantiﬁed using a Saﬁre plate-reader
(Tecan, M€annedorf, Switzerland) and XFluor4 software at 570 nm
with background subtraction at 650 nm. The absorbance
(A570nmeA650nm) correlates directly to living cell number in ATDC5
cells.
To assess total cell number, direct cell counting was performed.
ATDC5 cells plated at the same density were trypsinized for
2e5 min. After neutralizing with media, cell solution of each well
was counted using a hemocytometer. The total number of cells/well
is the counted number 104, where at least 3 wells/conditionwere
plated and counted on each day of the time-course.
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Fig. 1. Effect of GW3965 on longitudinal bone growth. Mouse tibiae were dissected
at E15.5, grown in culture for 6 days and treated every 48 h with DMSO as vehicle, or
various concentrations of GW3965. Bone length was measured on days 1 and 6 to
assess longitudinal growth. The values are presented as the mean of six independent
trials, with 95% CI.
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Limb buds (forelimb and hindlimb) of E11.5 CD1mouse embryos
were isolated and segmented, then dissociated in a solution con-
taining puck saline A (PSA), 10% (v/v) chick serum, and 2% (v/v)
dispase (50 caseinolytic units/ml, BD Biosciences, San Jose, CA) for
1.5 h at 37C and 100 rpm. The dispase activitywas neutralized and a
single cell suspension was extracted as described29,30. After cell
counting and a brief centrifugation, cells were resuspended in
micromassmedia at a concentration of 2.5107 cells/ml and plated
into six-wellNunc cell cultureplates, at eight 10ml drops/well. Plated
cells were incubated at 37C and 5% CO2 for 1 h to allow cell adher-
ence, followed by the addition of 2 ml/well of micromass media
supplemented with 10 mM b-glycerophosphate, 50 mg/ml ascorbic
acid, and the treatment of DMSOor GW3965. Cellswere cultured for
a period of 15 days, with media and treatment replenished daily.
Cell staining
Micromass cultures were stained with alcian blue as
described29. Both micromass cultures and ATDC5 cell cultures were
stained for alkaline phosphatase (ALP) activity as previously
described, with minor modiﬁcations29,30. Cells were washed twice
with cold PBS and ﬁxed in 10% formalin for 2 h at room tempera-
ture. After a 15 min incubation in ddH2O, cells were stained with an
ALP substrate containing 0.1 mg/ml naphthol AS-MX phosphate
(SigmaeAldrich), 0.5% N,N-dimethylformamide (SigmaeAldrich),
and 0.6 mg/ml Red Violet LB salt (SigmaeAldrich) in 0.2 M TriseHCl
(pH 8.3) for 45 min in the dark. All cells were washed with tap
water and allowed to air-dry before visualization. All images were
captured using the Leica EC3 microscope and Leica Application
Suite V3 Software.
Alcian blue staining in micromass cultures was quantiﬁed using
the Leica Application Suite V3 Software. For each time-point of each
individual trial, thresholds were selected for the parameters hue,
saturation and intensity using a representative control stain. These
threshold values were set in an attempt to encompass all dark blue
nodules within the micromass, and were applied to all treatment
stains within that same time-point. Values represent the total area
(mm2) of the micromass that fell within the threshold.
RNA isolation and real-time PCR
Total RNAwas isolated frommicromass culturesusing theRNeasy
mini kit (Qiagen, Toronto, ON) on days 3, 6, 9 and 12 according to the
manufacturer's instructions. Isolated RNA was quantiﬁed using a
Nanodrop 2000 spectrophotometer, and subsequently diluted
to 50 ng/ml. Template RNA was combined with commercially avail-
able probes from Applied Biosystems (Gapdh e Mm99999915_g1;
Mmp13 e Mm00439491_m1; Sox9 e Mm00448840_m1;
Col2a1eMm00491889_m1; Runx2eMm00501580_m1; Col10a1e
Mm00487041_m1; Cdkn1c e Mm01272135_g1; Ihh e
Mm00439613_m1; Pthlh e Mm00436057_m1; Acan e
Mm00545794_m1) and theTaqManone-stepmastermixkit tomake
a ﬁnal volume of 15 ml. Ampliﬁed target sequences were detected by
the ABI Prism 7900 HT sequence detection system (Perkin Elmer,
Waltham,MA). Expression values from all sampleswere normalized
to the internal control glyceraldehyde-3-phosphate (Gapdh) using
the deltaedelta cycle threshold (DDCT) method.
Protein extraction and Western blotting
Protein was harvested from ATDC5 cell cultures starting on day
3 of culture, then every 3 days thereafter. Cells were brieﬂy washed
with cold PBS, then suspended in radioimmunoprecipitation assay(RIPA) buffer and harvested. Following 30 min of incubation on ice,
cell lysates were centrifuged for 25 min at 4C at 14,000 rpm. The
supernatant was collected and protein concentration was quanti-
ﬁed using the Pierce BCA Protein Assay Kit (Pierce Biotechnology,
Rockford, IL) according to the manufacturer's instructions. Subse-
quently, 19 mg of protein was loaded and separated through sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
followed by protein transfer onto a polyvinylidene ﬂuoride (PVDF)
membrane (Bio-Rad Laboratories, Hercules, CA). The membrane
was then blocked with tris buffered saline-tween with 5% bovine
serum albumin (5% BSA-TBST), and incubated with primary anti-
body against p57/Kip2 (ab75974, Abcam, Cambridge, United
Kingdom) and b-actin (A5441, SigmaeAldrich). After washing in
TBST, the membrane was incubated with goat-anti-rabbit (sc-2004,
Santa Cruz), or goat-anti-mouse (sc-2005, Santa Cruz) immuno-
globulin G-horseradish peroxidase conjugated secondary antibody.
Signal visualization was performed using the Clarity Western ECL
Substrate (Bio-Rad) and the Bio-Rad ChemiDocMP Imaging System.
Statistical analysis
All data collected were from at least three independent trials.
Data were expressed as mean with 95% conﬁdence interval (CI)
(upper and lower limit), and P-values < 0.05 were considered sig-
niﬁcant. Statistical analysis was performed using one-way or two-
way analysis of variance (ANOVA) with the Tukey's post-hoc test
using GraphPad Prism 6.0 (GraphPad software, San Diego, CA).
Results
LXR activation alters growth plate morphology ex-vivo
To investigate the effect of LXR activation on longitudinal bone
growth, E15.5 tibiae were isolated and cultured in the presence of a
speciﬁc LXR agonist, GW3965. Tibiae treated with varying concen-
trations of GW3965 (0, 1, 2, 5 or 10 mM) did not reveal signiﬁcant
changes in growth, although growth appeared to be decreased in all
treated tibiae compared to the control (Fig. 1). To further examine
how GW3965 treatment affected E15.5 tibial growth plates, histo-
logical analysis was performed using Safranin-O/Fast Green staining
[Fig. 2(A)]. Quantitative measurements of individual growth plate
zones demonstrated the hypertrophic zone to be signiﬁcantly
reduced in lengthwhen treatedwith 1 mM, 5 mMand 10 mMGW3965
[Fig. 2(B)]. The length of the total growth plate and the proliferating
and resting zones combined remained comparable between treated
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Fig. 2. Histological analyses of GW3965-treated tibia organ cultures. (A) After 6 days in culture with DMSO as vehicle or different concentrations of GW3965, tibiae were
embedded and sectioned. Sections were stained with Safranin-O/Fast Green to visualize growth plate morphology. Representative images show the different zones of the growth
plate (R þ P ¼ resting and proliferating zones, H ¼ hypertrophic zone) (n ¼ 6). Scale bar ¼ 200 mm. (B) Histological quantiﬁcation was conducted on stained sections by measuring
individual growth plate zones. The values are presented as the mean of six independent trials, with 95% CI.
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LXR activation suppresses chondrocyte hypertrophy.
The cell-cycle exit marker p57 is decreased in GW3965-treated
tibiae
In order to gain insight into the mechanisms underlying the
shortened hypertrophic zones in GW3965-treated tibiae, the cell-
cycle exit marker p57 was studied using IHC [Fig. 3(A)]. Quantiﬁ-
cation of p57 IHC demonstrated that the number of positively
stained cells in GW3965-treated growth plate decreased relative to
control [Fig. 3(B)]. This demonstrates that the suppression of
chondrocyte hypertrophy observed in the tibial growth plate is in
part due to a delay in cell-cycle exit.
LXR activation results in decreased hypertrophy and increased
proliferation in ATDC5 cells
To further assess the role of LXR activation in endochondral bone
growth and development, ATDC5 cell cultures were used to analyze
chondrogenic differentiation over a continuous time-course.
Staining for alkaline phosphatase, a marker of chondrocyte hyper-
trophy, was markedly decreased upon treatment with 1 mM
GW3965 [Fig. 4(A)]. This reduction in staining was evident as early
as day 9 and persisted throughout the time-course [Fig. 4(A)]. Next,N
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Fig. 3. Immunohistochemical analyses of p57 protein localization in GW3965-treated
concentrations of GW3965, then ﬁxed and prepared for histology. Incubation of primary an
(A) Representative images were shown from four independent experiments. Scale bar ¼ 200
stained (brown) cells within a pre-set box centered on the pre-hypertrophic zone. Data arethe effect of GW3965 on proliferating chondrocytes was analyzed
using the MTT assay and direct cell counting. Our previous data had
shown that MTT values in ATDC5 cells and primary chondrocytes
directly correspond to cell numbers25,28. These methods show cell
number to consistently increase with GW3965 treatment [Fig. 4(B
and C)], suggesting the suppression of chondrocyte hypertrophy
by GW3965 to be secondary to prolonged proliferation.
LXR activation delays chondrocyte differentiation in micromass
cultures
We next used a micromass culture system consisting of mouse
embryonic mesenchymal cells plated in high-density droplets.
Compared to ATDC5 cells, this ex-vivo system is a more physio-
logical model of chondrogenesis. The amount of alkaline phos-
phatase staining was reduced in GW3965-treated micromasses
[Fig. 5(A)]. This reduction appeared to be more dose-dependent
than that shown by alcian blue [Fig. 5(B)]. Alcian blue, a stain that
detects the presence of glycosaminoglycans, was decreased upon
treatment of 1 mM GW3965, and slightly more so with 5 mM
GW3965 [Fig. 5(B)]. Quantiﬁcation using the Leica Application Suite
V3 Software demonstrated area of positive alcian blue staining to
decrease with GW3965 treatment [Fig. 5(C)]. For both stains, dif-
ferences between control and treatment became especially
apparent starting on day 6 and persisted throughout the time-2µ
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Fig. 4. Effect of GW3965 on chondrocyte proliferation and hypertrophy in ATDC5 cell culture. ATDC5 cells were plated at a density of 2  104 cells/well, induced to differentiate
on day 1, and cultured in the presence of either DMSO or 1 mM GW3965 starting on day 3. (A) Alkaline phosphatase staining was conducted on days 6, 9, 12, 15 and 18 to assess
chondrocyte hypertrophy (n ¼ 3). Scale bar ¼ 2 mm. (B) On days 6, 9, 12 and 15, cells were incubated with MTT and the absorbance of the converted dye was measured. Data are
presented as the mean of three independent trials, with 95% CI. (C) Cells were trypsinized and counted using a hemocytometer every 3 days starting on day 6. Values are presented
as the mean of three independent trials, with 95% CI.
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activation on suppression of chondrocyte hypertrophy, and inter-
estingly shows proteoglycan content to also be affected.
LXR activation down-regulates gene expression of late-stage
chondrogenic markers in micromass cultures
To better understand the mechanisms underlying the effect of
GW3965 on chondrogenic differentiation, real-time reverse-tran-
scription PCR was performed to examine the expression of variousgenes involved in cartilage development. This analysis was per-
formed using RNA extracted from micromass cultures treated with
DMSO or GW3965 (1 or 5 mM). Of the early chondrogenic markers
analyzed, mRNA levels of Col2a1 signiﬁcantly increased with
GW3965 treatment starting on day 9, while Sox9 and Aggrecan
expression remained unchanged [Fig. 6(A)]. Chondrocyte hyper-
trophy markers Runx2, Col10a1 and Mmp13 all signiﬁcantly
decreased upon treatment with GW3965 on day 12 of culture
[Fig. 6(B)]. Pthlh and Ihh, major regulators of chondrocyte prolifer-
ation and hypertrophy, decreased with treatment throughout the
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Fig. 5. Chondrogenic differentiation of micromass cultures with LXR activation. E11.5 mouse mesenchymal limb bud cells were plated in micromass cultures and cultured for 15
days in the presence of either DMSO or GW3965. For all staining, at least three independent experiments were used for each time-point, and representative images are shown.
(A) Alkaline phosphatase staining was performed every 3 days starting on day 3 to examine chondrocyte hypertrophy. Scale bar ¼ 1 mm. (B) Alcian blue content was examined
every 3 days starting on day 3 to assess proteoglycan content and early chondrogenesis. Scale bar ¼ 1 mm. (C) Alcian blue content was quantiﬁed using the Leica Application Suite
V3 Software, where thresholds were chosen for each time-point using the control image of that time-point. This threshold was then applied to all treatments to determine the total
area of positive staining. Values are represented as the mean with 95% CI (n ¼ 3).
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Fig. 6. Analyses of chondrogenic gene expression in micromass cultures with LXR activation. Micromass cultures composed of E11.5 mouse limb bud mesenchymal cells were cultured for 15 days and treated with different
concentrations of GW3965. RNAwas isolated every 3 days starting on day 3. Gene expression was analyzed by qRT-PCR and normalized to Gapdh. Data were expressed relative to values of day 3 control, and are represented as the mean
with 95% CI. (A) The mRNA expression levels of early chondrogenic markers Sox9, Col2a1, and Acan (n ¼ 4 or 6). (B) The mRNA expression levels of terminal chondrogenic markers Runx2, Col10a1 and Mmp13 (n ¼ 4). (C) The mRNA
expression levels of chondrocyte proliferation and hypertrophy regulating factors, Ckdn1c, Ihh and Pthlh (n ¼ 4).
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Although the expression of Cdkn1c demonstrated a slight increase
on day 12 with GW3965 treatment [Fig. 6(C)], both mRNA and
protein levels of p57 remained unchanged in ATDC5 cells upon
treatment (Supplementary Fig. 1). These results show that effects of
LXR activation on chondrocyte gene expression are consistent with
its effects on histological parameters, with the exception of p57,
potentially demonstrating context-speciﬁc expression patterns.
Discussion
Several nuclear receptors have been identiﬁed and shown to be
involved in endochondral ossiﬁcation through its implications on
Sox9 expression and other targets, including estrogen-related re-
ceptors (ERRs), retinoic acid receptors (RARs) and peroxisome
proliferator-activated receptor g (PPARg)32e35. However, much less
is known about the role of LXR. This study aimed to determine
whether LXR actively regulates the different stages of chondrogenic
differentiation. We used a synthetic LXR agonist, GW3965, to study
the speciﬁc effects of LXR activation on cartilage development.
The most prominent effect of LXR activationwas the decrease in
chondrocyte hypertrophy observed in three different chondrocyte
culture systems. Ex-vivo tibia organ cultures treated with GW3965
showed a signiﬁcant decrease in hypertrophic zone length. Simi-
larly, alkaline phosphatase staining was markedly decreased upon
LXR activation in both micromass cultures and in ATDC5 cell cul-
tures. Moreover, the mRNA levels of major chondrocyte hypertro-
phy markers Col10a1, Mmp13, and Runx2 were all decreased with
LXR activation. As such, LXR appears to be a negative regulator of
chondrocyte hypertrophy. As chondrocyte hypertrophy is one of
the largest contributors to skeletal growth36, GW3965's ability to
suppress hypertrophy also explains why a trend towards a decrease
in bone growth was observed with treatment.
The observed decrease in hypertrophic zone length can be
speculated to be the result of a few possible mechanisms. Terminal
chondrogenic differentiation could accelerate, and thus prompt
faster turnover of hypertrophic cartilage to bone31. Alternatively,
overall differentiation could decrease, resulting in the shortening
of each zone21. Our data from proliferation assays (both MTT
assays and cell-counts) conducted on ATDC5 cells suggest another
mechanism whereby hypertrophy is delayed through prolonged
proliferation. Although MTT proliferation assay results can only act
as correlates to cell proliferation37, previous studies using chon-
drogenic cell lines have shown MTT assay values to correlate with
actual cell numbers25,28.
The cyclin-dependent protein kinase inhibitor, p57, inhibits
proliferation and acts as both an inducer and marker of cell-cycle
exit in chondrocytes transitioning from the proliferative to hyper-
trophic state38. Immunohistochemical analysis showed the number
of cells positively stained for p57 to be decreased in the growth
plate of GW3965-treated tibiae compared to controls. Together
with the observed increase in proliferation, this suggests LXR
activation to enhance chondrocyte proliferation and delay cell-cy-
cle exit and onset of hypertrophic differentiation. In the cell culture
systems employed in this study, e.g., micromass cultures and
ATDC5 cell cultures, GW3965 treatment resulted in different effects
on p57 expression. Upon treatment, a slight increase in mRNA
levels was observed in micromass cultures, while mRNA and pro-
tein levels of p57 in ATDC5 cells remained unchanged. This suggests
that the authentic onset of p57 expression is largely dependent on
the presence of a proper three-dimensional spatial architecture of
the growth plate that is best emulated by ex-vivo organ cultures and
in-vivo model systems, but not the cell culture models used.
Indian hedgehog (Ihh) and parathyroid hormone like hormone
(Pthlh) control chondrocyte proliferation and differentiation,whereby Ihh, expressed by pre-hypertrophic and early hypertrophic
chondrocytes, stimulates Pthlh production to maintain prolifera-
tion39. We saw strong down regulation of Ihh mRNA expression
upon LXR activation. A study by Kim et al. demonstrates LXR acti-
vation through T0901317 or GW3965 to inhibit the expression of
hedgehog-target genes in calvaria organ cultures, which is in line
with our ﬁndings40. Inhibition of hedgehog signaling has also been
shown to decrease the expression of chondrocyte hypertrophy
markers and attenuate OA progression41. Thus, repression of Ihh
expression could be a key mechanism responsible for the delayed
hypertrophic differentiation seen upon LXR activation. As Pthlh is in
part regulated by Ihh42,43, our observed decrease in Pthlh expression
upon LXR activation may be a direct result of a decrease in Ihh
expression. Since the effects of LXR agonists on Ihh expression are
much stronger than those on Pthlh, the net effect of reduced Ihh
levels (delayed hypertrophy) appears to be dominating over those of
reduced Pthlh levels.
Previous studies have demonstrated that LXR activation protects
from OA progression18,19, but the mechanisms responsible for this
protective effect were not completely understood. Here we show
that suppression of hypertrophic differentiation of articular chon-
drocytes, which promotes OA progression7,13,14, is one such mech-
anism. Future studies will have to address the direct target genes of
LXR transcription factors in chondrocytes. Genome-wide proﬁling of
LXR targets has thus far been performed in liver cells, macrophages
and foam cells44e46. Among the new target genes of LXRa identiﬁed
by Feldmann et al. in foam cells is PARP-1, which encodes for the
enzyme Poly(ADP-ribose) polymerase-1. This enzyme is a ubiqui-
tous nuclear enzyme that is implicated in various biological pro-
cesses, including DNA damage repair47. Knockdown of PARP-1 has
also shown reduced cell proliferation in a human embryonic kidney
cell line48. These ﬁndings suggest that PARP-1 could be a candidate
gene up-regulated by LXR activation in chondrocyte differentiation.
Future studies integrating chromatin immunoprecipitation (ChIP)
sequencing and gene expression analyses will help identify LXR
target genes in cartilage and elucidate underlying mechanisms.
In summary, our study demonstrates the novel ﬁnding that LXR
activation by its synthetic agonist, GW3965, affects the regulatory
processes of chondrocyte differentiation. In particular, LXR activa-
tion suppresses chondrocyte hypertrophy through the prolonga-
tion of cellular proliferation by delaying cell-cycle exit. Further
investigation of the direct targets of LXR will shed light on how LXR
regulates this process. The ability of activated LXR to delay hyper-
trophic differentiation might be a useful attribute in the develop-
ment of disease-modifying drugs for OA treatment.
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